{"filings":[{"id":508399,"accession_number":"0001193125-26-229610","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2026-05-19T11:00:17+00:00","items":["8.01","9.01"],"status":"ready","headline":"Korro Bio selects KRRO-111 for AATD; pre-clinical results show >90% RNA editing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KRRO-111 is a GalNAc-conjugated oligonucleotide delivered subcutaneously for AATD.","In vivo editing >90% of SERPINA1 transcript, translating to ~90% repaired functional AAT protein in mouse model.","Repeated dosing nearly eliminated active Z-protein production; pre-existing aggregates progressively cleared.","Company plans to present additional KRRO-111 data at future scientific meeting.","CEO noted well-capitalized position to advance both KRRO-111 and KRRO-121 toward clinical data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94831,"accession_number":"0001193125-26-210291","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Korro Bio Q1 net loss narrows to $19.6M; cash at $157M; KRRO-121 filing on track for H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.6M vs $23.4M in Q1 2025; R&D spend down to $12.9M from $19.7M.","Cash, equivalents and marketable securities $157.1M as of March 31 (up from $85.2M), extending runway into H2 2028.","Closed oversubscribed $85M private placement led by Venrock Healthcare Capital Partners.","KRRO-121 regulatory filing for UCD/HE on track for H2 2026; AATD GalNAc candidate expected Q2 2026.","No collaboration revenue due to 12-month pause of Novo Nordisk partnership."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107487,"accession_number":"0001193125-26-104135","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Korro Bio reports FY2025 net loss $117.3M, nominates KRRO-121 for UCD/HE; $85M PIPE extends runway to H2 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 net loss $117.3M vs $83.6M in FY2024, driven by $30.9M non-cash impairment charges on KRRO-110 termination.","Cash $85.2M at Dec 31, 2025; plus $85M private placement in Mar 2026 extends runway into H2 2028.","Nominated KRRO-121 for UCD and HE; regulatory filing expected H2 2026.","GalNAc AATD program achieved >90% in vivo RNA editing; candidate nomination Q2 2026.","Collaboration revenue $6.4M from Novo Nordisk (paused); R&D expenses $65.6M, G&A $28.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107486,"accession_number":"0001193125-26-097575","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["1.01","2.02","3.02","7.01","9.01"],"status":"ready","headline":"Korro Bio raises $85M in PIPE led by Venrock; cash runway into H2 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$85M from 4,501,928 shares at $11.11 and 3,148,836 pre-funded warrants at $11.109.","Preliminary cash, equivalents, marketable securities of $85.2M as of Dec 31, 2025; runway through H2 2028.","Proceeds fund clinical milestones: KRRO-121 for urea cycle disorders and GalNAc-conjugated AATD program.","Closing expected March 10, 2026; placement agents include Citigroup, Cantor, Oppenheimer, William Blair."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107485,"accession_number":"0001193125-26-023436","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Korro Bio holds Analyst Day highlighting KRRO-121 for ammonia control","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Hosted virtual Analyst Day on Jan 27, 2026, presenting on KRRO-121 for ammonia control.","KRRO-121 described as a potential first-in-class treatment for ammonia control.","No specific clinical data or milestones disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107484,"accession_number":"0001193125-26-014087","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Korro Bio updates corporate presentation; no specific financial or operational details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company updated its corporate presentation on January 15, 2026 for investor meetings.","Selected slides from the updated presentation filed as Exhibit 99.1 to the 8-K.","No material financial or pipeline milestones were announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123844,"accession_number":"0001193125-25-324795","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Korro Bio amends employment agreement for General Counsel Jeffrey Cerio; raises base salary, severance, grants RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amended employment agreement for Jeffrey Cerio effective Dec 15, 2025; base salary increased to $425,000.","Severance increased: 9 months salary + prorated bonus outside CIC period; 12 months in CIC period.","Awarded $100,000 cash bonus: 50% paid Dec 31, 2025 and 50% paid June 30, 2026 (subject to continued employment).","Granted 41,902 RSUs vesting 50% on June 15, 2026 and 50% on Dec 15, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123843,"accession_number":"0001193125-25-277556","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["1.01","2.02","2.05","5.02","9.01"],"status":"ready","headline":"Korro Bio Q3 net loss $18.1M; cuts workforce 34%; Novo collaboration paused; KRRO-110 misses functional protein target","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, equivalents and securities $102.5M at Sept 30, 2025; net loss $18.1M for Q3.","Workforce reduction of ~34%; expects one-time restructuring charges of ~$2.4M in Q4 2025.","KRRO-110 produced functional M-AAT protein but peak total AAT ~10 µM missed protective 11 µM threshold; pivoting to GalNAc construct for AATD.","Nominated KRRO-121 for hyperammonemia; first-in-human filing anticipated H2 2026.","Novo Nordisk collaboration paused for 12 months; CMO Dr. Olugemo resigned effective Nov 12."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123842,"accession_number":"0001193125-25-234001","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Korro Bio CFO resigns; CEO takes interim CFO role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Vineet Agarwal resigns effective Oct 17, 2025; will advise for 30 days.","CEO Dr. Ram Aiyar named interim CFO in addition to CEO duties, no extra compensation.","Separation benefits include 9 months base salary ($352,500), prorated FY2025 target bonus ($149,400), and extended option exercise through Mar 31, 2027.","Departure is not related to any disagreement with management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140510,"accession_number":"0000950170-25-106910","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Korro Bio Q2 2025 net loss $25.8M; cash $119.6M; KRRO-110 interim data on track H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $119.6M as of June 30, 2025, expected to fund operations into 2027.","Net loss $25.8M for Q2 2025 vs $21.8M in Q2 2024; R&D expenses $21.0M (up from $17.1M).","Collaboration revenue of $1.5M from Novo Nordisk partnership; zero collaboration revenue in prior year quarter.","Phase 1/2a REWRITE trial of KRRO-110 for AATD: over 80% of planned healthy volunteers dosed; interim SAD readout expected H2 2025.","KRRO-110 received EMA Orphan Drug Designation for AATD; rare metabolic disorder development candidate to be announced by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":4010000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158208,"accession_number":"0000950170-25-087949","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K/A","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Korro Bio board adopts annual say-on-pay vote after shareholder advisory vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders voted for '1 Year' frequency for future advisory votes on NEO compensation at June 11, 2025 annual meeting.","Board determined that say-on-pay votes will be held annually until next frequency vote no later than 2031 annual meeting.","No other modifications were made to the original 8-K filed on June 11, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158210,"accession_number":"0000950170-25-084846","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Korro Bio stockholders elect three Class III directors, approve say-on-pay and auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Ram Aiyar, Jean-François Formela, Katharine Knobil as Class III directors for three-year terms ending 2028.","Advisory vote on named executive officer compensation approved with 7,972,389 for, 13,999 against.","Stockholders selected 1-year frequency for future say-on-pay votes (7,982,473 votes for 1 year).","Ratified Ernst & Young as independent auditor for FY2025 with 8,342,623 votes for, 8,369 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158209,"accession_number":"0000950170-25-065786","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Korro Q1 net loss $23.4M; workforce reduction of 20%, cash runway into 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $23.4M vs $19.6M YoY; collaboration revenue $2.6M from Novo Nordisk.","Cash, cash equivalents and marketable securities $139.0M, expected to fund operations into 2027.","Workforce reduction of approximately 20%; one-time restructuring charges ~$1.2M in Q2 2025.","Phase 1/2a REWRITE trial interim readout for KRRO-110 expected H2 2025; trial completion in 2026.","Expect to nominate second development candidate in 2025; Novo Nordisk cardiometabolic collaboration ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176574,"accession_number":"0001193125-25-064792","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Korro Bio CFO Vineet Agarwal returns from medical leave; Oliver Dolan named principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Vineet Agarwal reappointed as principal financial officer effective March 27, ending temporary medical leave since Feb 11.","CEO Ram Aiyar ceases interim CFO duties; remains President and CEO.","Oliver Dolan, SVP Finance, appointed principal accounting officer; granted 20,000-share stock option at closing price.","Option grant effective April 1, 2025; standard indemnification agreement entered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176573,"accession_number":"0000950170-25-040755","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Korro Bio reports FY2024 net loss $83.6M; cash $163.1M; KRRO-110 interim readout H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $83.6M (vs $81.2M in 2023); R&D expenses $63.6M; G&A $30.5M.","Cash, cash equivalents $163.1M; runway into H2 2026 expected to fund KRRO-110 trial.","KRRO-110 Phase 1/2a REWRITE trial: completed dosing first two cohorts; no SAEs; interim data H2 2025.","FDA granted Orphan Drug Designation for KRRO-110 for AATD.","Collaboration revenue $2.3M from Novo Nordisk partnership; second development candidate expected end 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176572,"accession_number":"0001193125-25-024305","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Korro Bio CFO Vineet Agarwal takes temporary medical leave; CEO Ram Aiyar named interim principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective Feb 11, 2025, CFO Vineet Agarwal on temporary medical leave from Korro Bio.","CEO Ram Aiyar appointed interim principal financial officer; no additional compensation.","Oliver Dolan, SVP Finance, appointed interim principal accounting officer.","Dolan has served as SVP Finance since Jan 2024; previously at Unity Biotechnology, Haven Healthcare, Compass Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176571,"accession_number":"0001193125-25-005020","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Korro Bio dosed first participants in Phase 1/2a study of KRRO-110 for AATD; interim data H2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First participants dosed in REWRITE Phase 1/2a study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD).","Interim data from Part 1 (single ascending doses) expected H2 2025; study completion anticipated in 2026.","Pipeline update: Korro targets 3 candidates, 2 tissue types, single platform (3-2-1 strategy) by 2027.","Novo Nordisk partnered program in cardiometabolic indication progressing towards clinic."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193425,"accession_number":"0000950170-24-129488","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Korro Bio receives Australian clearance to begin Phase 1/2a study of KRRO-110 for Alpha-1 Antitrypsin Deficiency","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Australian HREC approval and TGA clearance obtained for Phase 1/2a REWRITE study of KRRO-110 in AATD.","First participant dosing expected Q1 2025; interim readout H2 2025; study completion anticipated 2026.","KRRO-110 aims to edit RNA to produce functional M-AAT; in mouse model, >60% editing achieved at therapeutically relevant levels.","Study will evaluate safety, tolerability, PK/PD of single and multiple ascending doses in PiZZ genotype patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193424,"accession_number":"0000950170-24-125347","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Korro Bio reports Q3 net loss $21M, cash $169.1M; files clinical study for KRRO-110, partners Novo Nordisk","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.0M for Q3 2024 vs $18.5M in Q3 2023; R&D expenses $16.0M (up from $14.0M).","Cash and equivalents $169.1M as of Sep 30, 2024; cash runway into H2 2026.","Submitted regulatory filing in Australia for Phase 1/2 study of KRRO-110 in AATD; first dosing expected Q1 2025.","Announced collaboration with Novo Nordisk for up to two targets in cardiometabolic diseases; up to $530M in milestones plus royalties.","Appointed Jeffrey Cerio as General Counsel, Katharine Knobil to Board; formed Clinical Advisory Board."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193423,"accession_number":"0000950170-24-120282","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Korro Bio files first regulatory submission for KRRO-110 in AATD, expects first dosing Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Regulatory filing submitted to Australian Bellberry HREC for Phase 1/2 study of KRRO-110 in Alpha-1 Antitrypsin Deficiency.","First participant dosing anticipated in Q1 2025; interim readout expected H2 2025; study completion in 2026.","Formed Clinical Advisory Board of six lung and liver experts to guide development strategy.","KRRO-110 is first RNA editing oligonucleotide from Korro's OPERA platform, targeting SERPINA1 RNA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209745,"accession_number":"0000950170-24-106611","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Korro Bio partners with Novo Nordisk for up to $530M in RNA editing deal for cardiometabolic targets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $530M in upfront, development, and commercial milestone payments plus tiered royalties and R&D funding.","Upfront fee of $10M for first target; potential additional upfront for second target if nominated.","Korro grants exclusive worldwide license to Novo Nordisk for two undisclosed cardiometabolic targets using OPERA platform.","Korro responsible for preclinical development; Novo Nordisk may advance programs through clinical studies.","Deal allows Korro to retain internal pipeline focus while expanding RNA editing to high-prevalence diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209744,"accession_number":"0000950170-24-101395","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director David Lucchino resigns; Katharine Knobil appointed to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Lucchino resigned from board effective Aug 26, 2024; no disagreement with management or board.","Lucchino signed consulting agreement: $9k/quarter through 2026 annual meeting, then $2k/quarter through 2027; option grant (~$150k, capped 8k shares) at 2025 meeting, vesting at 2026 meeting.","Board reduced size from 7 to 6, then increased to 7 to appoint Katharine Knobil, M.D. as Class III director; also appointed to Compensation Committee.","Dr. Knobil will serve until 2025 annual meeting; receives standard non-employee director compensation and indemnification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209743,"accession_number":"0000950170-24-096172","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Korro Bio Q2 net loss $21.8M; cash $187.8M; KRRO-110 FIH filing on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.8M for Q2 2024, up from $17.6M in Q2 2023, driven by higher R&D and G&A costs.","Cash, equivalents & marketable securities total $187.8M as of June 30, 2024; runway into H2 2026.","Regulatory filing for KRRO-110 first-in-human trial in AATD expected in H2 2024.","Preclinical data showed >70% M-AAT protein in circulation with ~60% sustained editing efficiency.","Completed $70M private placement in April 2024 to support pipeline development."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227916,"accession_number":"0001193125-24-165684","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Korro Bio Chief Scientific Officer Steve Colletti to resign effective August 2, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steve Colletti, Ph.D., notified Korro Bio of his resignation as Chief Scientific Officer on June 17, 2024.","His resignation is effective August 2, 2024.","Korro Bio is a biotechnology company focused on RNA editing, traded on Nasdaq under ticker KRRO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227915,"accession_number":"0001193125-24-159933","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Korro Bio stockholders approve charter amendment limiting officer liability; reelect Behbahani and Pearson as directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to charter to limit officer liability per Delaware law approved with 5,876,891 votes for, 13,173 against; effective June 11, 2024.","Ali Behbahani reelected Class II director: 4,205,573 for, 1,687,334 withheld; 225,634 broker non-votes.","Timothy Pearson reelected Class II director: 5,889,522 for, 3,385 withheld; 225,634 broker non-votes.","Stockholders ratified Ernst & Young LLP as independent auditor for FY2024: 6,117,678 for, 615 against, 248 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227914,"accession_number":"0000950170-24-059498","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Korro Bio appoints Dr. Kemi Olugemo as Chief Medical Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Olugemo joined as CMO effective May 13, 2024; prior role was VP of Global Clinical Development at Ultragenyx.","Previously Head of Clinical Development at Laronde (now Sail Bio) and Executive Director at Ionis Pharmaceuticals.","Over 10 years of neurology and rare disease clinical development experience, including global approvals.","M.D. from University of Maryland School of Medicine with fellowship in Neuroimmunology & Multiple Sclerosis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227913,"accession_number":"0000950170-24-059491","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Korro Bio Q1 net loss $19.6M; appoints Kemi Olugemo as CMO; cash $138.8M plus $70M PIPE","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.6M in Q1 2024, unchanged from Q1 2023; R&D $13.6M, G&A $7.9M.","Cash $138.8M at Mar 31, 2024; after $70M April PIPE, pro forma ~$206M; runway into H2 2026.","Appointed Kemi Olugemo, MD, as Chief Medical Officer; she brings >10 yrs industry experience.","Regulatory filing for KRRO-110 (RNA editing for AATD) on track for H2 2024; interim data H2 2025.","$70M PIPE led by Deep Track Capital with Atlas Venture, NEA, and other healthcare investors."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227912,"accession_number":"0001193125-24-105037","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Korro Bio closes $70M private placement to fund Phase 1/2 trial of KRRO-110","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,249,283 shares at $56.00 per share for gross proceeds of ~$70M.","Led by Deep Track Capital; includes Atlas Venture, Blue Owl, NEA, Rock Springs, Tri Locum.","Proceeds plus existing $166.4M cash to fund Phase 1/2 trial of KRRO-110 in AATD through 2026.","Piper Sandler, RBC Capital, BMO Capital Markets acted as placement agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227911,"accession_number":"0001193125-24-100069","cik":1703647,"company_name":"Korro Bio, Inc.","ticker":"KRRO","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Korro Bio raises ~$70M in PIPE led by Deep Track Capital; pro-forma cash ~$236M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PIPE of 1,249,283 shares at $56.00 each for gross proceeds of ~$70M.","Pro-forma cash and equivalents ~$236M, including existing $166.4M as of 12/31/23.","Lead investor Deep Track Capital; participants include Atlas, Blue Owl, NEA, Rock Springs, Tri Locum.","Proceeds to fund Phase 1/2 trial of KRRO-110 in AATD, expected completion in 2026.","Regulatory filing for first-in-human study of KRRO-110 anticipated H2 2024; interim readout H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":193767247.28234017,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}